Recent Finacing
Recent Raise
Landos Biopharma develops orally active, gut‑restricted small molecules targeting the LANCL2 pathway for autoimmune diseases, advancing lead asset BT‑11 from Phase 1 into global Phase 2 trials for IBD.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Landos Biopharma.
